Bicycle Therapeutics PLC 8-K filings

Bicycle Therapeutics reported Q2 2026 financial results, highlighting positive clinical data for nuzefatide and zelenectide, an expanded advisory board, and a cash runway extending into 2030.

Bicycle Therapeutics plc announced that all proposals, including director re-elections and auditor ratification, were approved at its annual general meeting on June 17, 2026.

Bicycle Therapeutics announced encouraging initial Duravelo-2 and updated Duravelo-1 data for metastatic urothelial cancer, showing comparable efficacy to standard of care with a differentiated safety profile.

Bicycle Therapeutics reported Q1 2026 financial results, highlighting progress in nuzefatide development and a strategic reprioritization impacting workforce and pipeline focus.

Bicycle Therapeutics plc announced updates on its nuzefatide pevedotin program and EphA2 pipeline at the AACR Annual Meeting 2026, highlighting encouraging preliminary efficacy and differentiated tolerability.

Bicycle Therapeutics announced a strategic reprioritization, including a workforce reduction, to extend its cash runway into 2030 while focusing on next-generation therapeutics.

Bicycle Therapeutics plc announced the appointment of Travis Thompson as its new Chief Financial Officer, succeeding Alethia Young, effective January 29, 2026.

Bicycle Therapeutics highlights 2025 pipeline advancements and sets key strategic priorities for 2026, including clinical trial updates and an extended financial runway.

Bicycle Therapeutics provides an update on its clinical pipeline, including zelenectide pevedotin, and reports third-quarter 2025 financial results with $648.3 million in cash.

Bicycle Therapeutics appoints Roger Dansey, M.D., and Herv Hoppenot to its Board of Directors, adding extensive drug development and commercialization expertise.

Bicycle Therapeutics announced its second quarter 2025 financial results, reporting an increased net loss and implementing a strategic workforce reduction to extend its financial runway into 2028.

Bicycle Therapeutics plc announced that all nine proposals, including director re-elections, executive compensation, and auditor appointments, were duly passed by shareholders at its Annual General Meeting held on June 17, 2025.

Bicycle Therapeutics announces Q1 2025 financial results, highlighting progress in its oncology pipeline and a cash runway extending into the second half of 2027.

Bicycle Therapeutics reports additional human imaging data validating MT1-MMP as a novel cancer target and highlighting the potential of Bicycle Radioconjugates for radiopharmaceutical imaging.

Bicycle Therapeutics announces key leadership and board appointments, including a new chairman and chief medical officer, to strengthen its focus on cancer drug development.

Bicycle Therapeutics has set June 17, 2025, as the date for its Annual General Meeting and announced deadlines for shareholder proposals and director nominations.

Bicycle Therapeutics reports promising clinical trial results, FDA Fast Track designations, and a strong cash position extending into 2H 2027.

Bicycle Therapeutics reports positive Phase 1 trial results for zelenectide pevedotin in combination with pembrolizumab, along with strategic priorities and milestones for 2025.

Bicycle Therapeutics reported promising data for its zelenectide pevedotin program, particularly in patients with NECTIN4 gene amplification, and outlined a new development strategy focusing on this biomarker.

Bicycle Therapeutics reported promising clinical trial results for its oncology pipeline and a strong cash position of $890.9 million as of September 30, 2024.

Bicycle Therapeutics has released first human imaging data validating MT1-MMP as a novel cancer target and demonstrating the potential of their Bicycle Radionuclide Conjugates (BRC) for radiopharmaceutical use.

Bicycle Therapeutics shared updated clinical results for three of its drug candidates, showing promising response rates and safety profiles in various cancer types.

Bicycle Therapeutics announced positive progress in its clinical pipeline, a strengthened financial position with a $555 million private investment, and the formation of a Clinical Advisory Board.

Bicycle Therapeutics has fully repaid its $30 million loan with Hercules Capital, including interest and fees, totaling $31.9 million, and terminated the loan agreement.

Bicycle Therapeutics has filed a prospectus supplement for the resale of up to 37,656,764 ordinary shares by existing security holders.

Bicycle Therapeutics has entered into a securities purchase agreement to raise approximately $555 million through a private placement of American Depositary Shares and non-voting ordinary shares.

Bicycle Therapeutics successfully passed all resolutions at its annual general meeting on May 16, 2024, including the re-election of directors and the ratification of auditors.

Bicycle Therapeutics announced its first quarter 2024 financial results, highlighted by a cash balance of $457 million and continued advancement of its clinical pipeline.

Bicycle Therapeutics has appointed Felix J. Baker to its Board of Directors and entered into a registration rights agreement with Baker Brothers Life Sciences, L.P. and 667, L.P.

Bicycle Therapeutics announced promising clinical data for its pipeline, a new board member, and a strong cash position in its year-end 2023 update.